Genome sequencing projects, particularly that of the human
genome, have accelerated the revolution in the life sciences
begun in 1953 with the discovery of the structure of DNA.
Today, the principles elucidated by Watson and Crick, Boyer
and Cohen and Collins and Venter are providing unprecedented
opportunities to improve the quality of life around the world
through biotechnology. Whether it's discovering a cure for
a life-threatening disease or providing an environmentally
friendly process for producing better foods or industrial
materials, biotechnology will be important factor in tomorrow's
global economy.
The path, however, from discovery research to commercialization
and profitability is more complex than ever. Gene cloning
has given way to gene chips, microarrays and high throughput
screening. The genome has given way to the proteome, transcriptome
and metabolome. Bioinformatics is transforming databases into
knowledge bases and the traditional wet lab of test tubes
and burners is giving way to in silico genetics, e-R&D
and biosimulations. Pharmacogenomics and SNPs are helping
to create safer and more effective drugs while more and more
of the so-called "blockbuster" drugs are going off
patent.
Davis Bioscience Group can assist both investors and bioentrepreneurs
in capitalizing on these exciting new breakthroughs. Through
its network of accomplished and respected associates, Davis
Bioscience Group has the seasoned business experience and
in-depth understanding of the technology required to take
the bioentrepreneur from start to finish. The combination
of superior knowledge, strategic thinking, decisive action
and professionalism is Davis Bioscience Group's formula for
success. Davis Bioscience Group's primary areas of expertise
include:
· Strategy Planning
· Operations, Organization and Strategic Leadership
· Technology Management
· Biotechnology and Bioinformatics
· Management of Investment Capital
· Litigation Support
